Yuriy Mostovoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuriy Mostovoy has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Nataliia Slepchenko
National Pirogov Memorial Medical University, Vinnitsa, Ukraine
6 shared publications - Kostiantyn Dmytriiev
Vinnytsia National Pirogov Memorial Medical University, Vinnytsia
5 shared publications - Andrii Sidorov
National Pirogov Memorial Medical University, Vinnitsa, Ukraine
4 shared publications Nataliia Tsymbaliuk
National Pirogov Memorial Medical University, Vinnitsa, Ukraine
3 shared publications- Anna Demchuk
National Pirogov Memorial Medical University, Propedeutic Department of Internal Medicine; Department of Infection Diseases, Vinnytsya; Podilskiy Regional Oncological Center, Cytological Laboratory, Ukraine
2 shared publications Frank Cools
2 shared publications
Latest Publications
- Open Access
- 29 September 2022
- Published by Vinnytsia National Pyrogov Memorial Medical University in Reports of Vinnytsia National Medical University
- Vol. 26 (3) , 467-471
Impact of pharmacotherapy with tiotropium/olodaterol on the pulmonary function in COPD patients depending on the Arg16Gly polymorphism of ADRB2 gene
Annotation. Chronic obstructive pulmonary disease (COPD) is a prevalent chronic disease. Endogenic or genetic factors play a significant role in the COPD development. The aim of our study was to investigate a response to the tiotropium/olodaterol treatment in patients with different ADRB2 gene polymorphism. 100 patients with the diagnosis of COPD were included into the study. Pulmonary function testing was performed during all study visits. All patients received treatment according to GOLD 2019, which included a combination of long-acting beta-2 agonists (LABA) and long-acting muscarinic antagonists (LAMA). According to the results of genetic testing all patients were divided into 3 groups: Arg16Arg – 23 patients (23%), Arg16Gly – 39 patients (39%), Gly16Gly – 38 patients (38%). Statistical processing of research materials was carried out using the SPSS statistical program package for Windows version 26.0. Descriptive statistics were determined for each interval variable and presented as mean ± standard deviation (SD). Kolmogorov-Smirnov test, Mann-Whitney test and T-test, Wilkson test, t-test, Kruskal-Wallis test were used as part of the one-way ANOVA analysis, as well as with the analysis of covariance (ANCOVA) followed by pairwise comparison of groups using Bonferroni corrections. Groups did not differ by sex, age, part of smokers, COPD duration. There was significant difference in RLM at the time of inclusion (p=0.01). There was a significant difference in the Pain value at the time of study completion (р=0.024). When comparing values of SGRQ questionnaire, there was a significant difference in the scales of Impact (р=0.006) and Total score (р=0.021). Thus, group Gly16Gly had better dynamics of SF-36 and SGRQ values during the study. Despite the absence of significant difference we can state, that Gly16Gly genotype has better response to treatment when compared to Arg16Arg, which is probably conditioned by the development of sensitization of ADRB2 receptor in Arg16Arg group.
- 29 September 2022
- Published by Vinnytsia National Pyrogov Memorial Medical University in Reports of Vinnytsia National Medical University
- Vol. 26 (3) , 467-471
Open AccessImpact of pharmacotherapy with tiotropium/olodaterol on the pulmonary function in COPD patients depending on the Arg16Gly polymorphism of ADRB2 gene
Annotation. Chronic obstructive pulmonary disease (COPD) is a prevalent chronic disease. Endogenic or genetic factors play a significant role in the COPD development. The aim of our study was to investigate a response to the tiotropium/olodaterol treatment in patients with different ADRB2 gene polymorphism. 100 patients with the diagnosis of COPD were included into the study. Pulmonary function testing was performed during all study visits. All patients received treatment according to GOLD 2019, which included a combination of long-acting beta-2 agonists (LABA) and long-acting muscarinic antagonists (LAMA). According to the results of genetic testing all patients were divided into 3 groups: Arg16Arg – 23 patients (23%), Arg16Gly – 39 patients (39%), Gly16Gly – 38 patients (38%). Statistical processing of research materials was carried out using the SPSS statistical program package for Windows version 26.0. Descriptive statistics were determined for each interval variable and presented as mean ± standard deviation (SD). Kolmogorov-Smirnov test, Mann-Whitney test and T-test, Wilkson test, t-test, Kruskal-Wallis test were used as part of the one-way ANOVA analysis, as well as with the analysis of covariance (ANCOVA) followed by pairwise comparison of groups using Bonferroni corrections. Groups did not differ by sex, age, part of smokers, COPD duration. There was significant difference in RLM at the time of inclusion (p=0.01). There was a significant difference in the Pain value at the time of study completion (р=0.024). When comparing values of SGRQ questionnaire, there was a significant difference in the scales of Impact (р=0.006) and Total score (р=0.021). Thus, group Gly16Gly had better dynamics of SF-36 and SGRQ values during the study. Despite the absence of significant difference we can state, that Gly16Gly genotype has better response to treatment when compared to Arg16Arg, which is probably conditioned by the development of sensitization of ADRB2 receptor in Arg16Arg group.
- Open Access
- 25 May 2022
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- No. 2,p. 29-34
Impact of pharmacotherapy with tiotropium/olodaterol on the pulmonary function in COPD patients depending on the Arg16Gly polymorphism of ADRB2 gene
BACKGROUND. Chronic obstructive pulmonary disease (COPD) is a widespread chronic disease, that can be prevented and treated. Internal or genetic factors play a significant role in the COPD development. OBJECTIVE. To investigate a response to the tiotropium/olodaterol treatment in patients with different ADRB2 gene polymorphism. MATERIALS AND METHODS. 100 patients with the diagnosis of COPD were included into the study. Pulmonary function testing was performed during all study visits. All patients received treatment according to GOLD 2019, which included a combination of long-acting b2-agonists and long-acting muscarinic antagonists. According to the results of genetic testing all patients were divided into three groups: Arg16Arg – 23 patients (23 %), Arg16Gly – 39 (39 %), Gly16Gly – 38 (38 %). RESULTS. Groups did not differ by sex, age, part of smokers, COPD duration. There was a significant difference in force vital capacity (FVC), which was 66.92±4.33 % in Arg16Arg group, 79.75±3.51 % in Arg16Gly group and 76.59±2.73 % in Gly16Gly group (p=0.05). There was a weak negative correlation between Arg16Arg genotype and FVC (r=-0.204; p=0.043). In regression analysis Arg16Arg genotype was associated with 10.52 % lower FVC on average (odds ratio -10.523; 95 % confidence interval from -20.502 to -0.544; p=0.039). A statistically significant improvement of forced expiratory volume in the first second (FEV1) and FVC was observed in all groups during the study (pCONCLUSIONS. Arg16Arg genotype was associated with the lowest FVC values during all study visits. Combination of tiotropium/olodaterol was effective in improving pulmonary function in patients with different ADRB2 genotypes, which was demonstrated by a significant improvement of FEV1 and FVC in study groups during the study.
- 25 May 2022
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- No. 2,p. 29-34
Open AccessImpact of pharmacotherapy with tiotropium/olodaterol on the pulmonary function in COPD patients depending on the Arg16Gly polymorphism of ADRB2 gene
BACKGROUND. Chronic obstructive pulmonary disease (COPD) is a widespread chronic disease, that can be prevented and treated. Internal or genetic factors play a significant role in the COPD development. OBJECTIVE. To investigate a response to the tiotropium/olodaterol treatment in patients with different ADRB2 gene polymorphism. MATERIALS AND METHODS. 100 patients with the diagnosis of COPD were included into the study. Pulmonary function testing was performed during all study visits. All patients received treatment according to GOLD 2019, which included a combination of long-acting b2-agonists and long-acting muscarinic antagonists. According to the results of genetic testing all patients were divided into three groups: Arg16Arg – 23 patients (23 %), Arg16Gly – 39 (39 %), Gly16Gly – 38 (38 %). RESULTS. Groups did not differ by sex, age, part of smokers, COPD duration. There was a significant difference in force vital capacity (FVC), which was 66.92±4.33 % in Arg16Arg group, 79.75±3.51 % in Arg16Gly group and 76.59±2.73 % in Gly16Gly group (p=0.05). There was a weak negative correlation between Arg16Arg genotype and FVC (r=-0.204; p=0.043). In regression analysis Arg16Arg genotype was associated with 10.52 % lower FVC on average (odds ratio -10.523; 95 % confidence interval from -20.502 to -0.544; p=0.039). A statistically significant improvement of forced expiratory volume in the first second (FEV1) and FVC was observed in all groups during the study (pCONCLUSIONS. Arg16Arg genotype was associated with the lowest FVC values during all study visits. Combination of tiotropium/olodaterol was effective in improving pulmonary function in patients with different ADRB2 genotypes, which was demonstrated by a significant improvement of FEV1 and FVC in study groups during the study.
- 28 June 2021
- Published by Publishing Company VIT-A-POL in Ukrainian Neurological Journal
- No. 1—2,p. 30—37
Structure of cognitive disorders and predictors of their occurrence in patients after cardiac surgery
Objective — to determine the presence and severity of moderate cognitive disorders (CD) in patients before and after cardiac surgery in the early postoperative period Methods and subjects. 56 patients were examined, including 19 (33.9 %) men and 37 (66,1 %) women , mean age 60.86 ± 8.86. Cardiac surgery was performed for ischemic heart disease in 37 (66.1 %) patients, for valvular heart disease — in 19 (33.9 %, p = 0.02). Assessment of cognitive functions was performed before surgery, on the 3rd and 7th day of the postoperative period using the Montreal Cognitive Test. Results. Before surgery, most patients (75.0 %) had mild CRs, 5.4 % had moderate CRs (p <0.01), and 19.6 % had no CRs (p = 0.02). In general, the distribution by the severity of CR in the early postoperative period did not differ from that before surgery, but there were patients with severe CR (3.6 and 1.8 %, respectively, on the 3rd and 7th days, p = 0.05) ...In the structure of CD, on the 3rd day of the postoperative period, there was a significant decrease in visually constructive skills (4.07 versus 3.7; p < 0.001), a deterioration in the ability to consistently calculate (2.66 versus 2.45; p = 0.02), repetition phrases (1.16 versus 1.0; p = 0.02). On the 7th day of the postoperative period, there was a significant decrease in verbal speed (0.48 versus 0.32; p = 0.006) and an improvement in memory (1.79 versus 2.29; p = 0.01). Probable predictors of the onset of cognitive disorders in the early postoperative period are: a history of stroke — r = –0.282; p = 0.04. There was a correlation with the presence of atherosclerotic lesions of the coronary arteries according to coronary angiography (r = –0.259; p = 0.05), surgery performed under cardiopulmonary bypass (r = 0.29; p = 0.03), and a tendency towards statistical significance of correlation with the presence of signs of dyslipidemia according to lipid profile data (r = –0.227; p = 0.09). Conclusions. It was found that 75 % of patients had mild CR before surgery. The distribution according to the severity of CR in the early postoperative period differed from that before surgery by the appearance of patients with severe CR. In the CR structure, on the 3rd day of the postoperative period, a statistically significant decrease in visual‑constructive skills, a deterioration in the ability to consistently calculate and repeat a phrase were observed. On the 7th day, a statistically significant decrease in verbal speed and an improvement in memory were noted. Probable predictors of CR in the early postoperative period are a history of acute cerebrovascular accident, atherosclerotic lesion of the coronary arteries according to coronary angiography, surgery performed under cardiopulmonary bypass, the presence of signs of dyslipidemia according to lipid profile data.
- 28 June 2021
- Published by Publishing Company VIT-A-POL in Ukrainian Neurological Journal
- No. 1—2,p. 30—37
Structure of cognitive disorders and predictors of their occurrence in patients after cardiac surgery
Objective — to determine the presence and severity of moderate cognitive disorders (CD) in patients before and after cardiac surgery in the early postoperative period Methods and subjects. 56 patients were examined, including 19 (33.9 %) men and 37 (66,1 %) women , mean age 60.86 ± 8.86. Cardiac surgery was performed for ischemic heart disease in 37 (66.1 %) patients, for valvular heart disease — in 19 (33.9 %, p = 0.02). Assessment of cognitive functions was performed before surgery, on the 3rd and 7th day of the postoperative period using the Montreal Cognitive Test. Results. Before surgery, most patients (75.0 %) had mild CRs, 5.4 % had moderate CRs (p <0.01), and 19.6 % had no CRs (p = 0.02). In general, the distribution by the severity of CR in the early postoperative period did not differ from that before surgery, but there were patients with severe CR (3.6 and 1.8 %, respectively, on the 3rd and 7th days, p = 0.05) ...In the structure of CD, on the 3rd day of the postoperative period, there was a significant decrease in visually constructive skills (4.07 versus 3.7; p < 0.001), a deterioration in the ability to consistently calculate (2.66 versus 2.45; p = 0.02), repetition phrases (1.16 versus 1.0; p = 0.02). On the 7th day of the postoperative period, there was a significant decrease in verbal speed (0.48 versus 0.32; p = 0.006) and an improvement in memory (1.79 versus 2.29; p = 0.01). Probable predictors of the onset of cognitive disorders in the early postoperative period are: a history of stroke — r = –0.282; p = 0.04. There was a correlation with the presence of atherosclerotic lesions of the coronary arteries according to coronary angiography (r = –0.259; p = 0.05), surgery performed under cardiopulmonary bypass (r = 0.29; p = 0.03), and a tendency towards statistical significance of correlation with the presence of signs of dyslipidemia according to lipid profile data (r = –0.227; p = 0.09). Conclusions. It was found that 75 % of patients had mild CR before surgery. The distribution according to the severity of CR in the early postoperative period differed from that before surgery by the appearance of patients with severe CR. In the CR structure, on the 3rd day of the postoperative period, a statistically significant decrease in visual‑constructive skills, a deterioration in the ability to consistently calculate and repeat a phrase were observed. On the 7th day, a statistically significant decrease in verbal speed and an improvement in memory were noted. Probable predictors of CR in the early postoperative period are a history of acute cerebrovascular accident, atherosclerotic lesion of the coronary arteries according to coronary angiography, surgery performed under cardiopulmonary bypass, the presence of signs of dyslipidemia according to lipid profile data.
- Open Access
- 30 March 2021
- Published by Vinnytsia National Pyrogov Memorial Medical University in Reports of Morphology
- Vol. 27 (1) , 41-49
Sex-age features of the prevalence and structure of heart rhythm disorders in the patients with severe Covid-infection
There is growing evidence that arrhythmias are a major complication of COVID-19 infection. Inflammation of the myocardium, cytokine storm, hypoxia, changes of electrolyte levels, coronary vasospasm, microcloths may be factors that contribute to the development of arrhythmias and changes of the ECG. The aim of the study was to determine the sex and age characteristics of the prevalence and structure of cardiac arrhythmias in patients with severe COVID infection. In the study were examined 133 patients with severe COVID-19 infection, who were in the intensive care unit of the city clinical hospital №1 in Vinnytsia at the period from April to December 2020 and as a result of treatment with improved health were discharged from the hospital. Statistical processing of the obtained data was performed using the statistical software package SPSS 12.0 for Windows using parametric and non-parametric methods of statistical analysis. It was found that the most common comorbid pathologies of the patients with severe COVID-19 were – arterial hypertension 90 (67.7%), coronary heart disease 91 (68.4%), chronic heart failure 65 (48.9%), obesity 47 (35.3%) and diabetes mellitus 32 (24.1%). It was found that the prevalence of cardiac arrhythmias in patients with severe COVID-19 was 86 (64.7%) patients. Among all arrhythmias, tachyarrhythmias predominated – 68 (51.1%), in the structure of which sinus tachycardia was the most common in 45 (33.8%) and atrial fibrillation (AF) – in 19 (14.3%) patients, respectively. In turn, sinus tachycardia was significantly more common among women. The prevalence of bradyarrhythmias was 60 (45.1%), in the structure of which were dominated sinus bradycardia 16 (12%) and blockade of the right branch of the His bundle 30 (22.6%). Among men, there was a tendency to the predominance of complete left bundle branch block. The prevalence of ischemic changes and/or repolarization disorders according to the ECG was 119 (89.5%), in the structure of which were dominated the presence of inversion of the T wave 91 (68.4%) and depression of the ST segment 54 (40.6%). The mean age of the patients with ischemic ECG changes was significantly higher compared to patients without signs of repolarization disorders. Among men, there was a predominance of pancreatic hypertrophy and a tendency to predominance of left ventricular hypertrophy.
- 30 March 2021
- Published by Vinnytsia National Pyrogov Memorial Medical University in Reports of Morphology
- Vol. 27 (1) , 41-49
Open AccessSex-age features of the prevalence and structure of heart rhythm disorders in the patients with severe Covid-infection
There is growing evidence that arrhythmias are a major complication of COVID-19 infection. Inflammation of the myocardium, cytokine storm, hypoxia, changes of electrolyte levels, coronary vasospasm, microcloths may be factors that contribute to the development of arrhythmias and changes of the ECG. The aim of the study was to determine the sex and age characteristics of the prevalence and structure of cardiac arrhythmias in patients with severe COVID infection. In the study were examined 133 patients with severe COVID-19 infection, who were in the intensive care unit of the city clinical hospital №1 in Vinnytsia at the period from April to December 2020 and as a result of treatment with improved health were discharged from the hospital. Statistical processing of the obtained data was performed using the statistical software package SPSS 12.0 for Windows using parametric and non-parametric methods of statistical analysis. It was found that the most common comorbid pathologies of the patients with severe COVID-19 were – arterial hypertension 90 (67.7%), coronary heart disease 91 (68.4%), chronic heart failure 65 (48.9%), obesity 47 (35.3%) and diabetes mellitus 32 (24.1%). It was found that the prevalence of cardiac arrhythmias in patients with severe COVID-19 was 86 (64.7%) patients. Among all arrhythmias, tachyarrhythmias predominated – 68 (51.1%), in the structure of which sinus tachycardia was the most common in 45 (33.8%) and atrial fibrillation (AF) – in 19 (14.3%) patients, respectively. In turn, sinus tachycardia was significantly more common among women. The prevalence of bradyarrhythmias was 60 (45.1%), in the structure of which were dominated sinus bradycardia 16 (12%) and blockade of the right branch of the His bundle 30 (22.6%). Among men, there was a tendency to the predominance of complete left bundle branch block. The prevalence of ischemic changes and/or repolarization disorders according to the ECG was 119 (89.5%), in the structure of which were dominated the presence of inversion of the T wave 91 (68.4%) and depression of the ST segment 54 (40.6%). The mean age of the patients with ischemic ECG changes was significantly higher compared to patients without signs of repolarization disorders. Among men, there was a predominance of pancreatic hypertrophy and a tendency to predominance of left ventricular hypertrophy.
- Open Access
- 25 March 2021
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- No. 1,p. 5-14
The first data on international multicenter clinical study RheoSTAT-CP0698 on the efficacy and safety of Rheosorbilact® infusion in therapy of pneumonia
Adequate and effective treatment of severe pneumonia is especially relevant in present situation. The most problematic issue is infusion therapy. The current evidence and guidelines recommend balanced crystalloid infusion for patients with severe pneumonia and sepsis. The composition of Rheosorbilact® provides significant benefits in patients with severe infections, including respiratory infections. According to the results of the randomized open blinded end-point RheoSTAT-CP0698 study, administration of Rheosorbilact® to patients with pneumonia (intravenous infusion at a dose of 200-400 ml/day for 3 days) effectively improves the clinical condition, reduces the manifestations of (multi-) organ failure and endogenous intoxication. Small-volume infusion therapy promotes rapid normalization of circulating blood volume, stabilization of hemodynamics, acid-base, electrolyte and gas composition of the blood, significantly improves saturation and reduces tachypnea. The positive effect of therapy on renal function and inflammation has also been established. This therapy had a favorable safety profile (e. g., it did not lead to fluid overload, pulmonary edema, pleural effusion or other serious side effects, and was not associated with a clinically significant increase in endogenous serum lactate level). The RheoSTAT-CP0698 study substantiates the feasibility of using Rheosorbilact® in the complex treatment of pneumonia.
- 25 March 2021
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- No. 1,p. 5-14
Open AccessThe first data on international multicenter clinical study RheoSTAT-CP0698 on the efficacy and safety of Rheosorbilact® infusion in therapy of pneumonia
Adequate and effective treatment of severe pneumonia is especially relevant in present situation. The most problematic issue is infusion therapy. The current evidence and guidelines recommend balanced crystalloid infusion for patients with severe pneumonia and sepsis. The composition of Rheosorbilact® provides significant benefits in patients with severe infections, including respiratory infections. According to the results of the randomized open blinded end-point RheoSTAT-CP0698 study, administration of Rheosorbilact® to patients with pneumonia (intravenous infusion at a dose of 200-400 ml/day for 3 days) effectively improves the clinical condition, reduces the manifestations of (multi-) organ failure and endogenous intoxication. Small-volume infusion therapy promotes rapid normalization of circulating blood volume, stabilization of hemodynamics, acid-base, electrolyte and gas composition of the blood, significantly improves saturation and reduces tachypnea. The positive effect of therapy on renal function and inflammation has also been established. This therapy had a favorable safety profile (e. g., it did not lead to fluid overload, pulmonary edema, pleural effusion or other serious side effects, and was not associated with a clinically significant increase in endogenous serum lactate level). The RheoSTAT-CP0698 study substantiates the feasibility of using Rheosorbilact® in the complex treatment of pneumonia.
- Open Access
- 1 January 2021
- Published by Ukrainian Pulmonology Journal in Ukrainian Pulmonology Journal
- Vol. 29 (1) , 62-64
ASTHMA AND SMOKING
- 1 January 2021
- Published by Ukrainian Pulmonology Journal in Ukrainian Pulmonology Journal
- Vol. 29 (1) , 62-64
Open AccessASTHMA AND SMOKING
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 633
COPD exacerbations and adherence to treatment improvement:what goal can be achieved?
Background: The reduction of quantity of chronic obstructive pulmonary disease (COPD) exacerbations is key element for control of this disease. The aim of the study was to improve the adherence to COPD treatment and to decrease the quantity of COPD exacerbations because of it. Methods: The 156 patients with severe to very severe COPD were included into study. The information about exacerbations during 1 year before participation in the study was collected from routine medical records. The COPD exacerbations during 1 year in study were registered during the patients’ unscheduled visits to site. During the study patients were trained to use inhaler due to COPD correctly, they had to demonstrate correct technique of its use. The necessity to be within the regimen of basis therapy was discussed with them. T-test for independent samples and T-test for dependent samples were used for statistic processing. Results: During 1 year adherence to COPD treatment increased from 44.41 ± 1.07% to 75.21 ± 0.78%, i.e. on 30.8% (p<0.001). The total quantity of COPD exacerbations decreased from 2.07 ± 0.08 to 0.87 ± 0.07, i.e. by 58.0%. The quantity of severe exacerbations decreased from 1.10 ± 0.09 to 0.48 ± 0.07. i.e. by 56.4%. The total duration of exacerbations diminished from 20.06 ± 0.80 to 8.60 ± 0.61 days, i.e. by 57.1%. The total quantity of hospitalizations due to COPD exacerbations fell from 1.26 ± 0.10 to 0.48 ± 0.07, i.e. by 61.9%. Conclusion: Although the final level of adherence to treatment did not exceed 80%, the parameters that characterize COPD exacerbations burden can be decreased by more than 50%.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 633
COPD exacerbations and adherence to treatment improvement:what goal can be achieved?
Background: The reduction of quantity of chronic obstructive pulmonary disease (COPD) exacerbations is key element for control of this disease. The aim of the study was to improve the adherence to COPD treatment and to decrease the quantity of COPD exacerbations because of it. Methods: The 156 patients with severe to very severe COPD were included into study. The information about exacerbations during 1 year before participation in the study was collected from routine medical records. The COPD exacerbations during 1 year in study were registered during the patients’ unscheduled visits to site. During the study patients were trained to use inhaler due to COPD correctly, they had to demonstrate correct technique of its use. The necessity to be within the regimen of basis therapy was discussed with them. T-test for independent samples and T-test for dependent samples were used for statistic processing. Results: During 1 year adherence to COPD treatment increased from 44.41 ± 1.07% to 75.21 ± 0.78%, i.e. on 30.8% (p<0.001). The total quantity of COPD exacerbations decreased from 2.07 ± 0.08 to 0.87 ± 0.07, i.e. by 58.0%. The quantity of severe exacerbations decreased from 1.10 ± 0.09 to 0.48 ± 0.07. i.e. by 56.4%. The total duration of exacerbations diminished from 20.06 ± 0.80 to 8.60 ± 0.61 days, i.e. by 57.1%. The total quantity of hospitalizations due to COPD exacerbations fell from 1.26 ± 0.10 to 0.48 ± 0.07, i.e. by 61.9%. Conclusion: Although the final level of adherence to treatment did not exceed 80%, the parameters that characterize COPD exacerbations burden can be decreased by more than 50%.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Spirometry parameters and adherence to COPD treatment: is there association?
Background: The forced expiratory volume in 1s (FEV1) falls steadily in healthy people over the age of 40 by 22.4 ml per year (Thomas, E. at al., BMJ Open 2019; 9: 63-78) as well as in the patients with chronic obstructive pulmonary disease (COPD) III – IV GOLD by 35-59 ml per year (Tantucci, C. et al., International Journal of Chronic Obstructive Pulmonary disease 2012, 7: 95-99). The aim of the study was to detect whether spirometry parameters change in case of increase of adherence to treatment. Methods: The 156 patients were included into study. The study consisted of 5 visits and its duration was 12 months. At each visit spirometry was performed and the patients were trained to use inhaler due to COPD correctly. The short structured discussion was conducted with the patients. The comparison of parameters average values and reliability assessment of intergroup differences was conducted using T-test for independent samples and T-test for dependent samples. The statistical software package SPSS 21.0 was used for these purposes. Results: The adherence to COPD treatment raised from 44.41 ± 1.07% to 75.21 ± 0.78% (p <0.001). The adherence to treatment improvement had positive influence on some spirometry parameters. They are forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and forced expiratory volume in 6 s (FEV 6). So, FEV1 increased by 20 ml (1.16%, p=0.007), FVC by 90 ml (2.22%, p< 0.001) and FEV 6 by 50 ml (1.96%, p=0.002). Conclusion: In case of adherence to COPD treatment improve FEV1, FVC and FEV6 do not fall and even raised slightly but statistically significant.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Spirometry parameters and adherence to COPD treatment: is there association?
Background: The forced expiratory volume in 1s (FEV1) falls steadily in healthy people over the age of 40 by 22.4 ml per year (Thomas, E. at al., BMJ Open 2019; 9: 63-78) as well as in the patients with chronic obstructive pulmonary disease (COPD) III – IV GOLD by 35-59 ml per year (Tantucci, C. et al., International Journal of Chronic Obstructive Pulmonary disease 2012, 7: 95-99). The aim of the study was to detect whether spirometry parameters change in case of increase of adherence to treatment. Methods: The 156 patients were included into study. The study consisted of 5 visits and its duration was 12 months. At each visit spirometry was performed and the patients were trained to use inhaler due to COPD correctly. The short structured discussion was conducted with the patients. The comparison of parameters average values and reliability assessment of intergroup differences was conducted using T-test for independent samples and T-test for dependent samples. The statistical software package SPSS 21.0 was used for these purposes. Results: The adherence to COPD treatment raised from 44.41 ± 1.07% to 75.21 ± 0.78% (p <0.001). The adherence to treatment improvement had positive influence on some spirometry parameters. They are forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and forced expiratory volume in 6 s (FEV 6). So, FEV1 increased by 20 ml (1.16%, p=0.007), FVC by 90 ml (2.22%, p< 0.001) and FEV 6 by 50 ml (1.96%, p=0.002). Conclusion: In case of adherence to COPD treatment improve FEV1, FVC and FEV6 do not fall and even raised slightly but statistically significant.
- 1 January 2020
- Published by Ukrainian Pulmonology Journal in Ukrainian Pulmonology Journal
- No. 4,p. 21-23
COMPLIANCE WITH COPD TREATMENT: HOW TO ACHIEVE AND WHAT IS A RESULT?
- 1 January 2020
- Published by Ukrainian Pulmonology Journal in Ukrainian Pulmonology Journal
- No. 4,p. 21-23
COMPLIANCE WITH COPD TREATMENT: HOW TO ACHIEVE AND WHAT IS A RESULT?
- 29 September 2019
- p. 26-32
[NT-PROBNP LEVEL IN PATIENTS WITH LIVER CIRRHOSIS: RELATION TO PORTAL HYPERTENSION AND CARDIOVASCULAR CHANGES].
Cirrhotic cardiomyopathy (CC) is a frequent complication of liver cirrhosis (LC) and characterised by impaired contractile response to stress, altered diastolic relaxation, and QTc prolongation. Symptoms of CC can be masked by edematous ascitic syndrome, high cardiac output, hyperdynamic circulation and preserved left ventricular (LV) ejection fraction at rest. NT-proBNP is a sensitive marker of heart failure in patients with primary heart disease, but its diagnostic value in CC has not been determined. The aim of the study was to evaluate NT-proBNP levels in patients with LC and estimate its relationship with the severity of the main disease, cardiac and hemodynamic dysfunction. The study involved 90 patients with LC (age 49,9±1,92 years). LC decompensation was associated with an increase of end-systolic, end-diastolic volume (ESV, EDV), left ventricular myocardial index (LVMI), cardiac index (CI), decrease E/A and preserve ejection fraction (EF) at rest. Serum NT-proBNP levels in class A, B and C were 109±26.2, 174±17.6, 358±40.1 pg/ml (p˂0.05). The highest NT-proBNP levels were in patients with refractory ascites, severe esophagus varices, hepatorenal syndrome, hypoalbuminemia (374±49.4, 345±33.9, 467±47.4, 323±32.0 pg/ml), the lowest - in pre-ascitics patients (112±23.4 pg/ml). NT-proBNP was correlated with CTP, MELD, serum albumin, portal vein diameter (r= 0.550, 0.429, -0.334, 0.237, p˂0.05), eGFR, CI, EDV, LVMI, E/A (r= 0.419, 0.401, 0.296, 0.233, 0.325, p˂0.05). Thus, elevated levels of NT-proBNP may be an indicator of cardiac dysfunction in patients with LC.
- 29 September 2019
- p. 26-32
[NT-PROBNP LEVEL IN PATIENTS WITH LIVER CIRRHOSIS: RELATION TO PORTAL HYPERTENSION AND CARDIOVASCULAR CHANGES].
Cirrhotic cardiomyopathy (CC) is a frequent complication of liver cirrhosis (LC) and characterised by impaired contractile response to stress, altered diastolic relaxation, and QTc prolongation. Symptoms of CC can be masked by edematous ascitic syndrome, high cardiac output, hyperdynamic circulation and preserved left ventricular (LV) ejection fraction at rest. NT-proBNP is a sensitive marker of heart failure in patients with primary heart disease, but its diagnostic value in CC has not been determined. The aim of the study was to evaluate NT-proBNP levels in patients with LC and estimate its relationship with the severity of the main disease, cardiac and hemodynamic dysfunction. The study involved 90 patients with LC (age 49,9±1,92 years). LC decompensation was associated with an increase of end-systolic, end-diastolic volume (ESV, EDV), left ventricular myocardial index (LVMI), cardiac index (CI), decrease E/A and preserve ejection fraction (EF) at rest. Serum NT-proBNP levels in class A, B and C were 109±26.2, 174±17.6, 358±40.1 pg/ml (p˂0.05). The highest NT-proBNP levels were in patients with refractory ascites, severe esophagus varices, hepatorenal syndrome, hypoalbuminemia (374±49.4, 345±33.9, 467±47.4, 323±32.0 pg/ml), the lowest - in pre-ascitics patients (112±23.4 pg/ml). NT-proBNP was correlated with CTP, MELD, serum albumin, portal vein diameter (r= 0.550, 0.429, -0.334, 0.237, p˂0.05), eGFR, CI, EDV, LVMI, E/A (r= 0.419, 0.401, 0.296, 0.233, 0.325, p˂0.05). Thus, elevated levels of NT-proBNP may be an indicator of cardiac dysfunction in patients with LC.